#United States #San Diego #CND Life Sciences #Dementia Diagnosis #Skin Biopsy Tool

CND Life Sciences Set to Present Revolutionary Skin Biopsy Tool for Dementia at AAN 2025

CND Life Sciences, a trailblazing medical technology firm, is gearing up to unveil groundbreaking updates from three clinical trials focused on their innovative skin biopsy diagnostic tool, specifically designed for detecting dementia and related disorders. This exciting presentation will take place at the American Academy of Neurology (AAN) Annual Meeting 2025, running from April 5 to 9, at the San Diego Convention Center.

Focus of the Presentations

The studies presented will delve into the detection of phosphorylated alpha-synuclein (P-SYN) in individuals with dementia with Lewy bodies (DLB) and offer insights into the effectiveness of the diagnostic tool in clinical settings. The lead author of two of the key studies, Dr. Christopher Gibbons, who also serves as Chief Scientific Officer of CND Life Sciences and a professor of Neurology at Harvard Medical School, will lead the discussions. One of the pivotal objectives is to quantify changes in P-SYN over time, utilizing skin biopsies to track disease progression.

During the conference, Dr. Gibbons will share baseline data that assesses P-SYN and blood P-Tau 217 levels in patients with mild cognitive impairment—often a precursor to more severe forms of dementia such as Alzheimer’s disease. Another significant point of discussion will highlight a staggering annual increase of 52% in P-SYN in patients diagnosed with DLB, pointing to the critical role of these tests in monitoring disease progression.

Importance of Skin Biopsy Testing

The utility of skin biopsies as a non-invasive, outpatient procedure enables clinicians to accurately identify and assemble key information about patients suspected of having synucleinopathies. “This research further underscores that skin biopsies provide a straightforward test to help clinicians detect and quantify changes in P-SYN levels,” Dr. Gibbons elaborated.

Moreover, some findings indicate that a protocol involving fewer than three skin biopsies could significantly elevate the chances of false negatives, which can complicate diagnoses. Insight into the distinct patterns and distributions of synuclein subtypes further reinforces the value of comprehensive biopsy assessments.

Dr. Todd Levine, Chief Medical Officer of CND Life Sciences, comments on the critical nature of accurate diagnosis in patient care, “The Syn-One Test is a reliable, evidence-based tool that enhances our diagnostic capabilities when it comes to complex cases.” This ensures that healthcare providers can leverage minimally invasive methods to achieve clarity in their assessments.

Upcoming Presentation Details

The following abstracts will be presented during the AAN meeting:

• - Session 1: Innovations in Non-AD Dementia

- Abstract Title: A Longitudinal Quantitative Assessment of Phosphorylated Alpha-Synuclein Deposition in Dementia with Lewy Bodies
- Lead Author: Christopher Gibbons, MD, FAAN
- When: Sunday, April 6, at 2:12 PM PT

• - Abstract Title: The Syn-D Study Detection of Cutaneous Phosphorylated Alpha-Synuclein and blood P-Tau 217 in Patients with Mild Cognitive Impairment

- Lead Author: Christopher Gibbons, MD, FAAN
- When: Sunday, April 6, at 2:24 PM PT

• - Session P9: Movement Disorders

- Abstract Title: An Analysis of the Number of Skin Biopsies Needed in the Detection of Phosphorylated Alpha-Synuclein
- Lead Author: Todd Levine, MD
- Poster Presentation: Tuesday, April 8, from 11:45 AM – 12:45 PM PT

About CND Life Sciences

CND Life Sciences is dedicated to providing innovative diagnostic solutions for patients facing neurodegenerative diseases. With a CLIA-certified and CAP-accredited laboratory based in Scottsdale, Arizona, the firm has pioneered the Syn-One Test—a sophisticated method for aiding in the early diagnosis of neurodegenerative disorders. This test evaluates phosphorylated alpha-synuclein levels and allows the gathering of other critical pathological information through the analysis of small skin biopsy samples. Approximately 2,500 neurologists across 49 states have utilized this test, advancing both diagnosis and treatment strategies in complex cases.

For further details about CND Life Sciences and their diagnostic tools, visit cndlifesciences.com or follow them on LinkedIn.